Healthy.io Announces Collaboration with Boehringer Ingelheim to Increase Access to Testing for Kidney Disease

Healthy.io, the global leader in transforming the smartphone camera into a medical device, today announced the launch of a program with Boehringer Ingelheim Pharmaceuticals, Inc, a leading research-driven pharmaceutical company, that will support at-home testing and provide educational information for patients at risk of chronic kidney disease (CKD).

Through this collaboration, Boehringer Ingelheim will work with Healthy.io’s Minuteful Kidney™ test kit to explore the operational aspects of an at-home UACR (urine albumin-to-creatinine ratio) test kit – the first and only FDA-cleared, smartphone powered at-home ACR test – to at-risk, previously untested patients. This will help engage these patients in their kidney health by conducting a smartphone-powered test at the time and place of their choosing as a step-in screening for earlier identification of CKD.

“Minuteful Kidney is a catalyst to increase ACR testing at scale and support early detection of CKD,” said Paula LeClair, U.S. General Manager at Healthy.io. “Increasing test-adherence rates across all demographics and socio-economic groups leads to earlier detection of CKD and provides a path to care for those who need it. This is a true win-win – better health outcomes for patients, as well as potentially reduced healthcare costs.”

“Early screening and diagnosis is critical in delaying CKD progression, and may help reduce the potential for serious complications down the road,” said Lennart Jungersten, Senior Vice President, Medicine and Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. “By collaborating with Healthy.io, the ultimate goal is to increase testing for CKD so that those impacted can be evaluated for the appropriate care management.”

CKD is referred to as a “silent killer” because it often doesn’t have symptoms until very late stages. One in three Americans are at risk, including those with diabetes and hypertension. Yet most don’t know they have the condition until it progresses to end-stage renal disease (ESRD), eventually requiring dialysis and/or a kidney transplant. According to guideline-based care, people at risk should complete an annual UACR test, yet 80% do not.

Prior Healthy.io programs conducted in collaboration with leading health plans and provider systems have shown that at home testing with Minuteful Kidney raised testing adherence up to 50% at scale across previously untested populations irrespective of demographic and socioeconomic differences. This is particularly important as chronic, preventable illnesses disproportionately affect people of color. According to the National Kidney Foundation, Black or African Americans are almost 4 times more likely, and Hispanics or Latinos are 1.3 times more likely, to have kidney failure compared to white Americans.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”